Skip to main content

Table 2 Associations between clinicopathologic factors and density of CD8(+) T cells and programmed cell death-1 (PD-1) expression on CD8(+) T cells in primary tumors and lymph nodes of gastric adenocarcinoma

From: Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma

Variable Total (cases) Density of CD8(+) T cells in primary tumors [cases (%)] PD-1 expression on CD8(+) T cells [cases (%)]
Primary tumors Metastatic lymph nodes Tumor-free lymph nodes
Low High P Negative Positive P Negative Positive P Negative Positive P
Total 119 46 73   74 45   72 47   106 13  
Sex     0.263    0.155    0.434    0.982
 Male 78 33 (42.3) 45 (57.7)   45 (57.7) 33 (42.9)   45 (57.7) 33 (42.3)   69 (88.5) 9 (11.5)  
 Female 41 13 (31.7) 28 (68.3)   29 (70.7) 12 (29.3)   27 (65.9) 14 (34.1)   37 (90.2) 4 (9.8)  
Age (years)     0.631    0.940    0.852    0.934
 <55 55 20 (36.4) 35 (63.6)   34 (61.8) 21 (38.2)   34 (61.8) 21 (38.2)   49 (89.1) 6 (10.9)  
 ≥55 64 26 (40.6) 38 (59.4)   40 (62.5) 24 (37.5)   38 (59.4) 26 (40.6)   57 (89.1) 7 (10.9)  
Tumor location     0.782    0.464    0.552    0.648
 Cardia 49 19 (38.8) 30 (61.2)   32 (65.3) 17 (34.7)   30 (61.2) 19 (38.8)   43 (87.8) 6 (12.2)  
 Body 20 9 (45.0) 11 (55.0)   10 (50.0) 10 (50.0)   10 (50.0) 10 (50.0)   17 (85.0) 3 (15.0)  
 Antrum 50 18 (36.0) 32 (64.0)   32 (64.0) 18 (36.0)   32 (64.0) 18 (36.0)   46 (92.0) 4 (8.0)  
Cell differentiation     0.660    0.981    0.799    0.906
 Well to moderate 21 9 (42.9) 12 (57.1)   13 (61.9) 8 (38.1)   12 (57.1) 9 (42.9)   20 (95.2) 1 (4.8)  
 Poor (including Signet ring cell) 98 37 (37.8) 61 (62.2)   61 (62.2) 37 (37.8)   60 (61.2) 38 (38.8)   86 (87.8) 12(12.2)  
Lauren classification     0.011    0.103    0.061    0.239
 Intestinal 60 30 (50.0) 30 (50.0)   33 (55.0) 27 (45.0)   31 (51.7) 29 (48.3)   51 (85.0) 9 (15.0)  
 Diffuse and mixed 59 16 (27.1) 43 (72.9)   41 (69.5) 18 (30.5)   41 (69.5) 18 (30.5)   55 (93.2) 4 (6.8)  
Vascular invasion     0.302    0.114    0.454    0.572
 Yes 55 24 (43.6) 31 (56.4)   30 (54.5) 25 (45.5)   41 (64.1) 23 (35.9)   58 (90.6) 6 (9.4)  
 No 64 22 (34.4) 42 (65.6)   44 (68.8) 20 (31.3)   31 (56.4) 24 (43.6)   48 (87.3) 7 (12.7)  
Neural invasion     0.488    0.457    0.433    0.951
 Yes 77 28 (36.4) 49 (63.6)   46 (59.7) 31 (40.3)   23 (54.8) 19 (45.2)   38 (90.5) 4 (9.5)  
 No 42 18 (42.9) 24 (57.1)   28 (66.7) 14 (33.3)   49 (53.6) 28 (36.4)   68 (88.3) 9 (11.7)  
Clinical stage     0.018    0.113    0.122    0.357
 II–IIIA 12 1 (8.3) 11 (91.7)   10 (83.3) 2 (16.7)   10 (83.3) 2 (16.7)   11 (91.7) 1 (8.3)  
 IIIB–IIIC 107 45 (42.1) 62 (57.9)   64 (59.8) 43 (40.2)   62 (57.9) 45 (42.1)   95 (88.8) 12 (11.2)